RomânăFără categorie
Bone markers in cancer — Beta-CrossLaps, PINP and vitamin D: What does the doctor monitor and why?
Have you received an oncology diagnosis and your doctor has ordered tests with names like “beta-CrossLaps”, “PINP” or “vitamin D 25-OH”? Or maybe you are undergoing treatment with zoledronate or denosumab and don’t understand exactly what these blood tests are for? This guide explains in an understandable way why bones are a critical target organ in oncology and how these specialized markers can directly influence treatment decisions.
Why are bones so vulnerable to cancer?
Bones are not passive structures. They are living tissues, constantly remodeling, regulated by a delicate balance between the cells that build new bone ( osteoblasts ) and those that break it down ( osteoclasts ). When cancer interferes with this system, the balance is disrupted—and the consequences can be serious: pathological fractures, severe bone pain, spinal cord compression, and hypercalcemia (high blood calcium).
Bone metastases are common in certain types of cancer:
- Breast cancer — risk of bone metastases in 70–80% of patients with advanced disease
- Prostate cancer — bone metastases are present in 90% of advanced cases
- Multiple myeloma — bone is the main organ affected
- Lung cancer — bone metastases occur in 30–40% of patients
Bone markers in the blood allow the doctor to assess the intensity of bone destruction or formation , monitor the response to treatment, and detect complications before they become visible on imaging.
Beta-CrossLaps (CTX) — Bone Resorption Thermometer
What is it?
Beta-CrossLaps (also known as β-CTX-I or serum CTX) is a small fragment resulting from the degradation of type I collagen by osteoclasts — the cells that “eat” bone. The higher the level, the more active the bone destruction.
According to the 2026 ESCEO/IOF/IFCC international consensus, β-CTX-I is the global reference marker for bone resorption , recommended in both osteoporosis and oncology.
Reference values
| Population | Normal value |
| Premenopausal women | 0.10–0.50 ng/mL |
| Postmenopausal women | 0.10–0.70 ng/mL |
| Adult men | 0.10–0.55 ng/mL |
⚠️ Essential condition for collection: Blood must be collected in the morning between 7:30–10:00 , fasting (without food). Values vary significantly depending on the time of collection and diet.
What do elevated values mean?
Elevated CTX values indicate accelerated bone resorption and may be a sign of active bone metastases, hyperparathyroidism, or prolonged immobilization.
But there is also a lesser-known aspect: values that are too low can be dangerous . Under treatment with strong bisphosphonates (zoledronate) or denosumab, a CTX below 0.10 ng/mL signals excessive bone suppression — an important risk factor for osteonecrosis of the jaw (ONJ) or atypical femur fractures.
Direct therapeutic implications
Your doctor uses CTX to monitor your response to anti-resorptive therapy. A reduction of more than 30% from baseline confirms that treatment with zoledronate or denosumab is working. If CTX does not decrease enough, it may be necessary to adjust the dose or change the therapeutic agent.
PINP — Bone builder, measured in blood
What is it?
PINP (Procollagen Type I N-Terminal Propeptide) is a molecule released into the circulation when osteoblasts synthesize new collagen — that is, when bone is actively being built . It is the international reference marker for bone formation , confirmed by the ESCEO/IOF/IFCC consensus in 2026.
Reference values
- 20–80 µg/L (premenopausal women)
- Postmenopausal women and older men may have slightly higher values.
What does PINP tell us in cancer?
In oncology, PINP has two major uses:
1. Monitoring anabolic therapy (with PTH analogues)
If you are receiving teriparatide or abaloparatide for severe chemotherapy- or corticosteroid-induced osteoporosis, an increase in PINP of more than 10 µg/L from baseline at 3 months confirms that the bone is responding to treatment.
2. Bone metastases with formative component
Prostate cancers and some breast cancers produce osteoblastic metastases (which form excess bone). In these cases, PINP can be significantly elevated and serves as a marker of bone tumor activity.
📌 Important for patients with chronic kidney disease: In advanced renal failure, PINP and CTX accumulate in the blood due to reduced renal clearance. In these situations, the 2026 guidelines recommend the preferential use of bone alkaline phosphatase (BSAP) and TRACP5b (tartrate-acid phosphatase) as alternative reference markers.
Bone Alkaline Phosphatase (BSAP) — Marker of mineral formation
What is it?
BSAP is the bone-specific isoenzyme of alkaline phosphatase, synthesized by osteoblasts during the bone mineralization process.
Normal values: 15–60 U/L (or 7–30 µg/L in mass units)
When is it useful in oncology?
- Osteoblastic metastases (prostate cancer, breast with formative component): BSAP may be massively increased
- Paget’s disease — levels of 100–300 U/L are characteristic
- Chronic renal bone disease : is the marker of choice when PINP and CTX are not interpretable
Therapy
The treatment of choice for Paget’s disease is zoledronate 5 mg intravenously — a single annual infusion, with response monitored by BSAP. A decrease in BSAP under treatment confirms remission of Paget’s activity.
Vitamin D (25-OH) — The invisible foundation of any bone treatment
Why is vitamin D critical in oncology?
Vitamin D deficiency is extremely common in cancer patients — due to immobilization, chemotherapy, corticosteroids, and malnutrition. Its importance for bone markers is fundamental: without adequate vitamin D, no treatment with potent bisphosphonates works properly , and the risk of acute hypocalcemia after zoledronate or denosumab is significant.
Reference values (2026)
| Level | Interpretation |
| > 30 ng/mL (> 75 nmol/L) | Conventional sufficiency |
| 20–30 ng/mL | Insufficiency |
| < 20 ng/mL | Shortcoming |
According to the Endocrine Society 2024 guidelines, there is no longer a single universal threshold of “sufficiency”, but the classic thresholds remain useful in clinical practice.
Supplementary Protocol (2026)
- Correction of deficiency : 6,000 IU/day for 4–12 weeks, then maintenance doses
- Maintenance : 800–2,000 IU/day for adults; up to 4,000 IU/day in obesity, malabsorption, or darker skin pigmentation
- Before initiating zoledronate or denosumab: if 25-OH-vitamin D < 50 nmol/L, supplementation is mandatory — specialist consultation is recommended
Intact PTH (1-84) — The calcium sentinel in cancer
What is it?
Parathyroid hormone (PTH) is the main regulator of calcium, phosphorus, and vitamin D. Secreted by the parathyroid glands, PTH increases calcium from the bone, kidneys, and intestine when blood calcium levels fall.
Normal values: 10–65 pg/mL
Malignant hypercalcemia — a common oncological emergency
One of the most important applications of PTH in oncology is differentiating the cause of hypercalcemia (elevated calcium):
- Increased PTH = primary hyperparathyroidism (parathyroid adenoma) → surgical treatment; according to a meta-analysis published in 2024, primary hyperparathyroidism is associated with a 61% increase in cardiovascular mortality
- Low or undetectable PTH + elevated calcium = malignant hypercalcemia (common in myeloma, lung cancer, breast), caused by PTHrP (PTH-like peptide secreted by tumor cells) or extensive bone metastases
Malignant hypercalcemia is a medical emergency treated with aggressive intravenous hydration and intravenous zoledronate or denosumab. Low PTH confirms nonparathyroid origin and quickly guides therapeutic decision.
Beware of interference!
Biotin supplements (commonly used in hair/nail supplements) can interfere with some PTH tests, giving falsely low values. The 2026 guidelines recommend discontinuing biotin at least 2 days before PTH collection.
Summary — Bone markers and direct therapeutic implications
| Marker | Normal value | Key therapeutic implication |
| Beta-CrossLaps (CTX) | < 0.50 ng/mL | CTX < 0.10 ng/mL under bisphosphonates → ONJ risk; monitored monthly in zoledronate/denosumab therapy |
| PINP | 20–80 µg/L | Increase > 10 µg/L at 3 months under teriparatide = confirmed anabolic response |
| BSAP | 15–60 U/L | The marker of choice in chronic kidney disease and osteoblastic metastases |
| Vitamin D (25-OH) | > 30 ng/mL | Mandatory supplementation before initiating bisphosphonates/denosumab |
| Intact PTH | 10–65 pg/mL | Low PTH + high calcium = malignant hypercalcemia → urgent iv zoledronate |
🦴 Bone Markers in Cancer — Explanatory Table for Patients
📊 TABLE 1 — What each marker measures and what the values mean
| Marker | Meaning: what does it do in the body? | Normal value | INCREASED value — what does it mean? | LOW value — when is it a concern? |
| Beta-CrossLaps (CTX) | It measures how quickly the bone is destroyed . The higher it is, the faster the bone is degrading. | < 0.50 ng/mL | ✅ Natural if you are in menopause or immobilized ; ⚠️ Worrying if you have active bone metastases or hyperparathyroidism | ⚠️ Below 0.10 ng/mL under treatment = risk of mandibular necrosis (jaw bone) or atypical fractures |
| PINP | It measures how actively new bone is being built . | 20–80 µg/L | PTH (teriparatide) treatment that works; healing fractures; formative bone metastases (prostate) | Confirmed effect of bisphosphonates (zoledronate) — the bone is no longer destroyed; it is NOT a bad sign in this context |
| Bone Alkaline Phosphatase (BSAP) | bone-building cells (osteoblasts). | 15–60 U/L | Bone metastases that stimulate bone formation (prostate, breast cancer); Paget’s disease of bone | Active anti-osteoporosis treatment; long-term corticosteroids |
| Vitamin D (25-OH) | It shows the body’s vitamin D reserves — the foundation of bone health . | > 30 ng/mL | Rare (supplement overdose > 150 ng/mL) | ⚠️ < 20 ng/mL = deficiency; must be corrected before treatment with zoledronate or denosumab |
| Intact PTH (1-84) | Parathyroid hormone — regulates calcium and phosphorus in the blood and bones. | 10–65 pg/mL | Primary hyperparathyroidism (parathyroid adenoma); vitamin D deficiency; chronic kidney disease | ⚠️ Low PTH + high calcium = malignant hypercalcemia (medical emergency) — common in myeloma, lung cancer, breast |
📊 TABLE 2 — When to harvest and how to prepare
| Marker | Sample type | When is it harvested? | Special preparation conditions |
| Beta-CrossLaps (CTX) | Venous blood | Morning — mandatory between 7:30–10:00 | ✅ Fasting (not until evening); same time interval for each collection for correct comparison |
| PINP | Venous blood | Morning (recommended) | Does not require strict conditions; ideal in the morning |
| BSAP | Venous blood | Any time of day | No dietary restrictions |
| Vitamin D (25-OH) | Venous blood | Any time of day | No special restrictions |
| Intact PTH | Venous blood | In the morning , fasting | ⚠️ Stop taking biotin supplements 2 days before — they can give falsely low results on some tests |
📊 TABLE 3 — Direct therapeutic implications (what medical decision does each marker influence)
| Marker | Clinical situation | What medical decisions does it influence? | Specifically, what is happening? |
| CTX > 0.50 ng/mL in a patient with bone cancer | Accelerated bone resorption | The doctor initiates treatment with zoledronate (Zometa) or denosumab (Prolia/Xgeva) | Goal: reduce the risk of pathological fracture |
| CTX decreasing by > 30% from baseline under treatment | Confirmed therapeutic response | The doctor continues the current regimen | It means that the anti-resorption treatment is working |
| CTX < 0.10 ng/mL under bisphosphonate treatment | Excessive bone suppression | The doctor may reduce the dose or change the dosing interval. | Risk of osteonecrosis of the jaw and atypical fractures |
| PINP increases by > 10 µg/L at 3 months under teriparatide | Confirmed anabolic response | The doctor continues the anabolic treatment | The bone is actively rebuilding — an excellent sign |
| Vitamin D < 50 nmol/L (< 20 ng/mL) | Confirmed deficiency | The doctor postpones zoledronate/denosumab and prescribes additional emergency doses | Risk of severe acute hypocalcemia if zoledronate is administered without prior correction |
| Low PTH + high calcium | Malignant hypercalcemia | Medical emergency — hospitalization, intravenous hydration, IV zoledronate | Differentiation from primary hyperparathyroidism — completely different treatments |
| Increased PTH + increased calcium | Primary hyperparathyroidism (parathyroid adenoma) | Surgical evaluation (parathyroidectomy) or treatment with cinacalcet | Associated with increased cardiovascular mortality if untreated — meta-analysis 2024 |
📊 TABLE 4 — Which type of cancer benefits most from monitoring these markers
| Type of cancer | Priority bone markers | Why are they important? |
| 🎗 ️ Metastatic breast cancer | CTX, PINP, Vitamin D, PTH | Risk of bone metastases in 70–80% of advanced cases; fractures dramatically reduce quality of life |
| 🔵 Advanced prostate cancer | CTX, BSAP, PINP | Bone metastases occur in 90% of advanced cases; BSAP monitors the prostate-specific formative (osteoblastic) component |
| 🫁 Lung cancer | CTX, Vitamin D, PTH | Bone metastases in 30–40% of patients; malignant hypercalcemia is more common than in other cancers |
| 🩸 Multiple myeloma | CTX, PINP, BSAP, PTH, Vitamin D | Bone is the main organ affected ; massive bone destruction; malignant hypercalcemia = frequent emergency in myeloma |
| ✅ Any cancer under treatment with zoledronate/denosumab | CTX (required) | Routine monitoring for the prevention of jaw necrosis and dose adjustment |
📊 TABLE 5 — Vitamin D supplementation: practical guide for oncology patients (2026)
| Vitamin D Level | Interpretation | What does the doctor do? | Indicative doses (2026) |
| > 30 ng/mL | ✅ Enough | SUPPORT | 800–2,000 IU/day |
| 20–30 ng/mL | ⚠️ Insufficient | Moderate supplementation | 2,000–4,000 IU/day |
| < 20 ng/mL | ❌ Deficiency | Urgent correction before zoledronate/denosumab | 6,000 IU/day × 4–12 weeks, then maintenance |
| < 12.5 nmol/L (< 5 ng/mL) | ❌ Severe deficiency | Intensive correction + specialist consultation | Special forms (calcidiol) in patients with liver or kidney problems |
⚠️ Special attention: Patients with obesity , malabsorption (post-bariatric surgery, celiac disease) or darker skin pigmentation may require doses up to 4,000 IU/day for maintenance.
🔄 TABLE 6 — Recommended monitoring frequency (how often the tests are done)
| Clinical situation | CTX | PINP | Vitamin D | PTH |
| Initiation of treatment with zoledronate/denosumab | Before the first dose | Before the first dose | Mandatory before | As needed (if calcium is abnormal) |
| Under active treatment with zoledronate | At 3–6 months | Optional at 6 months | At 6 months | If calcium changes |
| Teriparatide initiation (anabolic treatment) | Baseline | At 0, 3 and 6 months | Before the start | Optional |
| Suspicion of bone metastases | Urgent | Urgent | Urgent | If increased calcium |
| Hypercalcemia (increased calcium in the blood) | — | — | It may be useful | Urgently required |
💡 VISUAL SUMMARY — The traffic light of values
| 🟢 GREEN — All good | 🟡 YELLOW — Attention, monitoring | 🔴 RED — Urgent medical action |
| CTX < 0.50 ng/mL (without treatment) | CTX 0.50–0.80 ng/mL | CTX < 0.10 ng/mL under bisphosphonates (risk of ONJ) |
| PINP 20–80 µg/L | PINP > 100 µg/L (without anabolic treatment) | Low PTH + High Calcium (malignant hypercalcemia) |
| Vitamin D > 30 ng/mL | Vitamin D 20–30 ng/mL | Vitamin D < 20 ng/mL before zoledronate |
| PTH 10–65 pg/mL | PTH > 65 pg/mL with normal calcium | PTH > 100 pg/mL with elevated calcium |
Disclaimer: Reference values may vary slightly depending on the laboratory and method used. Always refer to the ranges indicated on your test report and discuss the results with your healthcare professional.
How can Oncoexpertai help you?
If you have recently received analyses with these markers and do not know how to interpret them in the context of your diagnosis, the Oncoexpertai.com platform can be a structured starting point. Our Artificial Intelligence algorithms correlate your values with current international guidelines (NCCN, ESMO, ESCEO/IOF 2026) and generate a preliminary assessment that you can use as a basis for discussion with your oncologist or endocrinologist.
Don’t show up for the consultation with misunderstood tests. Just bring the complete file and the right questions.
📋 [Upload your analyses to Oncoexpertai.com and receive a preliminary AI-assisted assessment]
Disclaimer: The information in this article is for informational and educational purposes only. It does not constitute a medical diagnosis, does not replace the consultation of a specialist doctor, and does not represent a personalized therapeutic recommendation. Any medical decision should be made exclusively after consultation with a qualified doctor, based on a complete assessment of your health condition. Reference values may vary slightly depending on the laboratory and method used — always refer to the ranges indicated on the analysis report.
Bibliography
- Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2020;31(12):1650-1663. doi:10.1016/j.annonc.2020.07.019.
- Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International. 2011;22(2):391-420. doi:10.1007/s00198-010-1501-1.
- Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer. Journal of Clinical Oncology. 2010;28(35):5132-5139. doi:10.1200/JCO.2010.29.7101.
- Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822. doi:10.1016/S0140-6736(10)62344-6.
- Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaw—2022 Update. Journal of Oral and Maxillofacial Surgery. 2022;80(5):920-943. doi:10.1016/j.joms.2022.02.008.
- Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290.
- Endocrine Society. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2023;108(3):507-528. doi:10.1210/clinem/dgac621.
Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI